April 16, 2026 – Vaderis Therapeutics

Skip to content

Home
Medical Need
Our Science
Our Program
Our Team
News

Home
Medical Need
Our Science
Our Program
Our Team
News

Vaderis Expanded Access Policy >

Home
Medical Need
Our Science
Our Team
Our Program
News
Contact Us
Expanded Access Policy

Home
Medical Need
Our Science
Our Team
Our Program
News
Contact Us
Expanded Access Policy

Vaderis News |

08/11/2026

Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia

Vaderis News |

04/16/2026

Vaderis Announces Participation in Mass General Brigham Life Changing Research Town Hall

Vaderis News |

12/02/2025

Vaderis Therapeutics Announces The New England Journal of Medicine Publishes Engasertib Proof-of-Concept and Long-Term Extension Results

Vaderis News |

11/17/2024

Vaderis Receives FDA Fast Track Designation for VAD044 for the Treatment of Hereditary Hemorrhagic Telangiectasia

Vaderis News |

11/05/2024

Vaderis Announces Acceptance of Abstract on VAD044 Proof-of-Concept Clinical Trial

Vaderis News |

08/27/2024

Vaderis Announces Positive Clinical Proof-of-Concept Trial in HHT

Home
Medical Need
Our Science
Our Program
Our Team
News

Home
Medical Need
Our Science
Our Program
Our Team
News

© 2026 Vaderis Therapeutics. Vaderis™ is a trademark of Vaderis Therapeutics AG in the United States, European Union, and Switzerland.

Social

Privacy Statement

Contact

Switzerland
Building WSJ-350
Lichtstrasse 35
CH-4056 Basel
+1 844 823 3747

USA
250 Parkway Drive
Suite 360
Lincolnshire, IL 60069
+1 844 823 3747

Home
Medical Need
Our Science
Our Program
Our Team
News

Home
Medical Need
Our Science
Our Program
Our Team
News

Social

Privacy Statement

Contact

Terms of Use

USA
250 Parkway Drive
Suite 360
Lincolnshire, IL 60069
+1 844 823 3747

Switzerland
Building WSJ-350
Lichtstrasse 35
CH-4056 Basel
+1 844 823 3747

© 2026 Vaderis Therapeutics.
Vaderis™ is a trademark of Vaderis Therapeutics AG in the United States, European Union, and Switzerland.